Abstract:Background: To evaluate the performance of fully automated deep learning (DL) algorithm for staging hepatic fibrosis and distinguishing fibrosis from normal people based on MR images with or without non-image information.Methods: 500 patients were retrospectively enrolled from two hospitals. Model DL were built using delayed phase MR images to assess fibrosis stages. In addition, different models which combined model DL with non-image information including biomarkers (APRI and FIB-4), virus status (hepatitis B and C virus tests), and MR information (manufactures and static magnetic field) were built. The AUROCs were compared between different models using Delong test, the sensitivity and specificity of both model DL and model Full (model DL combined with all non-image information) were compared with experienced radiologists and biomarkers using McNemar’s test.Findings: In the test set, the AUROC (with 95% confidence intervals) values of model Full for diagnosing fibrosis stages F0-4, F1-4, F2-4, F3-4 and F4 were 0.99 (0.94-1.00), 0.98 (0.93-0.99), 0.90 (0.83-0.95), 0.81 (0.73-0.88) and 0.84 (0.76-0.90), respectively, which outperformed model DL on diagnosing F0-4 and F1-4. Compared with the radiologists, model Full showed better specificity for fibrosis stage F0-4, better sensitivity for the other four classification tasks. While compared with biomarkers, both model DL and model Full showed significantly higher specificity in staging F3-4 and F4.Interpretation: Deep learning-based model DL and model Full using delayed phase MR images provides a promising non-invasive assessment tool for the staging liver fibrosis with a performance superior to experienced radiologists and biomarkers (APRI and FIB-4) , which may be helpful to screen out CLD patients from normal individuals, instruct which patients need treatment and prevent patients from progressing to decompensated cirrhosis by paying more attention to patients with compensated cirrhosis (F4).Funding: This work was supported by the National Natural Science Foundation of China (grant numbers 81401406) and Innovative Research Team of High-level Local Universities in Shanghai. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscriptDeclaration of Interest: The authors declare that they have no conflict of interestEthical Approval: This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH

Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis

Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model

AI-based Digital Pathology Provides Newer Insights into Lifestyle Intervention-Induced Fibrosis Regression in MASLD: an Exploratory Study.

Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions

Analytical and Clinical Validation of AIM-NASH: A Digital Pathology Tool for Artificial Intelligence-based Measurement of Nonalcoholic Steatohepatitis Histology

An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials

Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology

Validation of a whole slide image management system for metabolic-associated steatohepatitis for clinical trials

Qfibs: an Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients with Nonalcoholic Steatohepatitis

Liver fibrosis phenotyping and severity scoring by quantitative image analysis of biopsy slides

Use of Artificial Intelligence (AI) in the Identification and Quantification of Hepatic Steatosis in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH

The Use of Artificial Intelligence in the Liver Histopathology Field: A Systematic Review

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease

Impact of Artificial Intelligence Assistive Tool on the Histopathologic Review of Fibrosis in Non-Alcoholic Steatohepatitis Patients

AI Digital Pathology Using qFibrosis Shows Heterogeneity of Fibrosis Regression in Patients with Chronic Hepatitis B and C with Viral Response

Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis

Deep Learning-Based Automated Assessment of Hepatic Fibrosis on Magnetic Resonance Images and Non-Image Data

acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study

Quantitative assessment of myocardial fibrosis by digital image analysis: An adjunctive tool for pathologist "ground truth"